Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 25 to Delist and Deregister Contingent Value Rights for APP Pharmaceuticals
Published: Mar 08, 2011
SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that on March 4, 2011, it filed a Form 25 with the NASDAQ and the United States Securities and Exchange Commission with respect to its Contingent Value Rights (“CVRs”) listed on the NASDAQ Capital Market. As previously disclosed in its 10-K filing on February 23, 2011, the Form 25 will delist the CVRs from the NASDAQ and deregister the CVRs under Section 12(b) of the Securities and Exchange Act of 1934 (the “Exchange Act”). The NASDAQ suspended trading of the CVRs effective the close of trading on March 4, 2011. On or about March 15, 2011, the Company intends to suspend its reporting requirements under the Exchange Act pending deregistration of the CVRs.